Clinical analysis of surgical treatment of portal hypertension

Xin-Bao Xu, Jing-Xiu Cai, Xi-Sheng Leng, Jia-Hong Dong, Ji-Ye Zhu, Zhen-Ping He, Fu-Shun Wang, Ji-Run Peng, Ben-Li Han, Ru-Yu Du

Xin-Bao Xu, Xi-Sheng Leng, Ji-Ye Zhu, Fu-Shun Wang, Ji-Run Peng, Ru-Yu Du, Department of Hepatobiliary Surgery, People’s Hospital, Peking University, Beijing 100044, China
Xin-Bao Xu, Department of Hepatobiliary Surgery, Airforce General Hospital, Beijing 100036, China
Jing-Xiu Cai, Zhen-Ping He, Jia-Hong Dong, Ben-Li Han, Center of Hepatobiliary Surgery, Southwest Hospital, The Third Military Medical University, Chongqing 400038, China
Correspondence to: Xin-Bao Xu, Department of Hepatobiliary Surgery, People’s Hospital, Peking University, Beijing 100044, China. x_xb@163.net
Telephone: +86-10-68792703
Received: 2004-06-29 Accepted: 2004-07-11

Abstract

AIM: To review the experience in surgery for 508 patients with portal hypertension and to explore the selection of reasonable operation under different conditions.

METHODS: The data of 508 patients with portal hypertension treated surgically in 1991-2001 in our centers were analyzed. Of the 508 patients, 256 were treated with portaazygous disconnection (PAD), 167 with portasystemic shunt (PSS), 62 with selective shunt (SS), 11 with combined portasystemic shunt and portaazygous devascularization (PSS+PAD), 9 with liver transplantation (LT), 3 with union operation for hepatic carcinoma and portal hypertension (HCC+PH).

RESULTS: In the 167 patients treated with PSS, free portal pressure (FPP) was significantly higher in the patients with a longer diameter of the anastomotic stoma than in those with a shorter diameter before the operation (P<0.01). After the operation, FPP in the former patients markedly decreased compared to the latter ones (P<0.01). The incidence rate of hemorrhage in patients treated with PAD, PSS, SS, PSS+PAD, and HCC+PH was 21.09% (54/256), 13.77% (23/167), 11.29% (7/62), 36.36% (4/11), and 100% (3/3), respectively. The incidence rate of hepatic encephalopathy was 3.91% (10/256), 9.58% (16/167), 4.84% (3/62), 9.09% (1/11), and 100% (3/3), respectively while the operative mortality was 5.49% (15/256), 4.22% (7/167), 4.84% (3/62), 9.09% (1/11), and 66.67% (2/3) respectively. The operative mortality of liver transplantation was 22.22% (2/9).

CONCLUSION: Five kinds of operation in surgical treatment of portal hypertension have their advantages and disadvantages. Therefore, the selection of operation should be based on the actual needs of the patients.

Key words: Portal hypertension; Surgical operation; Shunt
Xu XB, Cai JX, Leng XS, Dong JH, Zhu JY, He ZP, Wang FS, Peng JR, Han BL, Du RY. Clinical analysis of surgical treatment of portal hypertension. World J Gastroenterol 2005; 11 (29): 4552-4559
http://www.wjgnet.com/1007-9327/11/4552.asp

INTRODUCTION

In order to discuss operation indications, the data of 508 patients with portal hypertension treated surgically with portaazygous disconnection (PD), portasystemic shunt (PSS), selective shunt (SS), combined portasystemic shunt and portaazygous devascularization (PSS+PAD), liver transplantation (LT), and union operation for hepatic carcinoma and portal hypertension (HCC+PH) in 1991-2002 in our centers were analyzed.

MATERIALS AND METHODS

General data
Of the 508 patients, 425 were males and 83 females, aged 3-71 years (average 40.8 years). Three hundred and fifty-eight patients (70.47%) had a history of bleeding from the upper digestive tract, 150 patients (37.24%) had esophageal varices in different degrees with no history of bleeding from the upper digestive tract. Child-Pugh classification of liver function showed grade I in 260 patients, grade II in 164, grade III in 84. Etiology was posthepatic cirrhosis in 468 patients, biliary cirrhosis with biliary tract stenosis in 22, extrahepatic portal obstruction in 6, alcoholic cirrhosis in 8, schistosomiasis cirrhosis in 3, and idiopathic portal hypertension in 1.

Types of operation
Portaazygous disconnection (PAD) was performed in 256 patients (50.39%); portasystemic shunt (PSS) in 167 patients (32.87%, Table 1); selective shunt (SS) including distal splenorenal shunt (DSRS), distal spleno caval shunt (DSCS), coronary vein-left renal vein shunt and coronary vein-caval shunt in 62 patients (12.20%, Table 2).

Statistical analysis
The data were expressed as mean±SD, and analyzed with SPSS 10.0 for Windows. P<0.05 was considered statistically significant.

RESULTS

Free portal pressure (FPP)
The changes of free portal pressure (FPP) in 215 cases....
were observed before and after operation. The results are summarized in Table 3.

The results showed that FPP in the four groups of operation showed a marked post-operative decrease, especially in the PSS group with a diameter of anastomotic stoma in 8-12 mm compared to pre-operation ($P<0.01$). The pre-operation FPP in the PSS (diameter 8-12 mm) group was notably higher than that in other groups ($P<0.01$). The decreased absolute value of post-operation FPP in the PSS (diameter 8-12 mm) group (1.23±0.5 kPa) was also much higher than that in the PAD group (0.5±0.47 kPa) and SS group (0.51±0.46 kPa, $P<0.01$). No significant difference was found in the post-operation FPP of the above-mentioned four groups ($P>0.05$).

The FPP in 9 of 11 patients who underwent combined PSS+PAD decreased 0.79 kPa (81 cm H$_2$O) averagely after operation with no change of FPP in the other 2 patients. The degrees of esophageal varices in 7 of the 11 patients were alleviated with no change in the other 4 patients after operation as confirmed by barium meal.

### Table 3. Changes of free portal pressure (FPP) in three types of operation (mean±SD)

| Types of operation | Cases | Pre-operation (kPa) | Post-operation (kPa) |
|--------------------|-------|---------------------|----------------------|
| Portacaval shunt (PCS) | 62    | 3.85±0.59           | 3.26±0.45            |
| Portacaval shunt with prosthetic H-graft (PCS-H) | 25 | 3.78±0.50           | 3.26±0.57            |
| Mesocaval shunt (MCS) | 66    | 4.29±0.80           | 3.11±0.63            |
| Inferior mesocaval shunt (IMCS) | 26 | 3.91±0.48           | 3.12±0.46            |
| Juxtalsplenocaval shunt (JSCS) | 42 | 3.78±0.50           | 3.26±0.57            |
| Selective shunt (SS) | 42    | 3.85±0.59           | 3.26±0.45            |

### Hepatic encephalopathy

The total incidence rate of hepatic encephalopathy was 6.50% (33/508). The incidence rate of hepatic encephalopathy in patients treated with PAD, PSS, SS, PSS+PAD, and HCC+PH was 3.91% (10/256), 9.58% (16/167), 4.84% (3/62), 9.09% (1/11), and 100% (3/3), respectively.

### Operative mortality and its causes

The total operative mortality was 5.91% (30/508).

**PAD** The operative mortality was 5.86% (15/256). The cause of death was rebleeding. The high mortality was associated with severe disease. After being discharged from hospital, 21 cases died of rebleeding (10 cases), primary hepatocellular carcinoma (5 cases), liver function failure (5 cases) and malignant lymphoma (1 case).

**PSS** The operative mortality was 4.19% (7/167). Three patients died of severe hepatorenal syndrome, two died of rebleeding after operation, two underwent emergency MCS (12 mm in diameter of the anastomotic stoma), and died of hepatic encephalopathy 5 d after operation due to the improper operation method and large diameter of the anastomotic stoma. After being discharged from hospital, 16 cases died of primary hepatocellular carcinoma (5 cases), liver function failure (7 cases) and of rebleeding (4 cases).

**SS** The operative mortality was 4.84% (3/62). Three patients died of cerebral hemorrhage 5 d after operation, hepatorenal syndrome, and, rehemorrhage and infection in the subphrenic area and left lung. After discharge, two patients died of primary peritonitis, one of severe hepatitis, one of rebleeding.

**PSS+PAD** The operative mortality was 9.09% (1/11), this patient died of persistent deterioration of hepatic function and renal failure.

### HCC+PH

The operative mortality was 66.67% (2/3). One patient died of postoperative hemorrhage, the other died of hepatic failure. The last one succumbed to hepatic function failure 10 mo later after operation.

### Liver transplantation

We performed liver transplantation in 9 (1.77%) cases. The operative mortality was 2/9 (22.22%). The major reason of death was liver failure and infection after operation.

### Portacaval shunt for patients with portal hypertension combining ascites

Nineteen patients with ascites before operation underwent portacaval shunt. They all had hematemesis, dark stools, moderate and severe esophageal varices, ascites, and no hypertension and kidney disease. The liver function of all

---

**Table 1 Patients treated with PSS**

| Types of operation           | Cases |
|------------------------------|-------|
| Portacaval shunt (PCS)       | 14    |
| Portacaval shunt with prosthetic H-graft (PCS-H) | 25 |
| Mesocaval shunt (MCS)        | 66    |
| Inferior mesocaval shunt (IMCS) | 26 |
| Splenorenal shunt (SRS)      | 12    |
| Juxtalsplenocaval shunt (JSCS) | 16 |
| Branch of mesenterico-caval shunt (BMCS) | 5 |
| Inferior meso-left renal vein shunt | 2 |
| Colonic media vein-caval shunt | 1 |
| **Total**                    | **167** |

**Table 2 Patients treated with selective shunt (SS)**

| Types of operation                        | Cases |
|-------------------------------------------|-------|
| Distal splenocaval shunt (DSCS)           | 42    |
| Distal splenorenal shunt (DSRS)           | 16    |
| Coronary vein-caval shunt                 | 4     |
| **Total**                                 | **62** |

### Rehemorrhage

Ninety-one of the five hundred and eight cases (16.8%) had rehemorrhage. The incidence rate of hemorrhage in patients treated with PAD, PSS, SS, and PSS+PAD was 21.09% (54/256), 13.77 (23/167), 11.29 (7/62), and 36.36% (4/11), respectively. Twenty-four (44.44%) of the fifty-four rebleeding patients treated with PAD had rebleeding within a year after operation, the incidence rate of rehemorrhage was 9.38% (24/256). Fourteen cases had rebleeding 5 years after PAD. Hepatectomy combined with splenic artery ligation, coronary and cardia and fundus varix ligature, or portacaval shunt with H-grafts (8 mm in diameter) was performed in three patients with hepatocellular carcinoma complicated by portal hypertension. The incidence rate of rebleeding was 100% (3/3).
the patients was Child’s grade B, and their HBsAg was positive. Eleven patients underwent portacaval shunt with H-graft, and eight patients, portacaval side-to-side anastomosis. No ascites were found by B-type ultrasound reexamination in the abdominal cavity before discharge. Hepatic tissue biopsy showed liver cirrhosis. But mild and moderate hepatic coma occurred in three patients with diameter of anastomotic stoma of 8-10 mm after operation.

**Emergency operation for massive hemorrhage of gastrointestinal tract due to portal hypertension**

Twenty (3.94%) of the above-mentioned patients underwent emergency surgery. Ten of the patients (50%) had massive hemorrhage in gastrointestinal tract for the first time, the other 10 patients had a past medical history of massive hemorrhage in the gastrointestinal tract. They received endoscopic sclerotherapy (four cases) and loop ligation of varices (two cases), TIPSS (one case), balloon tamponade compression by a four-lumen tube (three cases). The causes of portal hypertension were cavernous transformation of portal vein, idopathic portal hypertension, and postphatic cirrhosis. Liver function was Child’s grade A (2 cases), Child’s grade B (7 cases), Child’s grade C (11 cases). Of the 20 cases, 12 cases received emergency PSS, 8 emergency PAD (gastroesophageal devascularization, 4 cases had ligation of splenic artery without splenectomy). The ratio of preoperative liver function as Child’s grade C was 58.33% (7/12) in the PSS group and 50% (4/8) in the PAD group. Postoperative mean loss of FFP was 9.6 cm H$_2$O in the PSS group and 1.8 cm H$_2$O in the PAD group. Surgical hemostasis had an effect on all the patients. Of the eight patients who underwent PAD, none had hepatic encephalopathy, five recovered smoothly, three (37.5%) had rehemorrhage within 2 wk after operation. We could not determine whether rupture of varices or hemorrhagic gastritis was the cause of postoperative bleeding. Of 12 patients who received PSS, 3 (25%) had hepatic encephalopathy, 2 (16.67%) rehemorrhagia, 4 died of liver failure. The total operative mortality was 25%. The operative mortality was 33.33% in the PSS group and 12.5% in the PAD group.

**DISCUSSION**

Portal hypertension refers strictly to an increase in the portal venous pressure (>5 mm Hg or 7 cm H$_2$O). Based on data in China, the normal portal venous pressure ranges from 13 to 24 cm H$_2$O, its mean value is 18 cm H$_2$O. Portal hypertension can be diagnosed when free portal venous pressure exceeds 25 cm H$_2$O, but the term is used to the clinical syndrome associated with an increased portal venous pressure characterized by splenomegaly and the development of abnormal portalsystemic venous anastomosis. Increased resistance to blood flow in the portal venous system is the most important cause, though increased portal blood flow may contribute to it in a few cases. The causes of increased portal venous resistance may lie in the presinusoidal vessels outside the liver or in the intrahepatic vessels at pre-sinusoidal, sinusoidal or post-sinusoidal levels. No consistent therapeutic method has been successful due to its complex etiology, pathophysiology and hemodynamics. Which kind of surgical treatment should be used depends on portal hemodynamics, etiology, age, liver pathology, liver function, bleeding history of upper digestive tract, size of spleen and hypersplenism.

**PAD**

PAD has no significant effect on portal perfusion. Nutritional factors such as insulin and glucagons are favorable for maintaining normal liver function. Portal hypertension is important in maintaining hepatopetal blood flow during liver cirrhosis. The present study showed that FPP of the pre-PAD-operation decreased by 0.59 kPa averagely compared to that of post-PAD-operation ($P<0.01$). In a small number of patients treated with PAD, the mean FPP decreased much more than 0.59 kPa, suggesting that PAD is an effective hemostatic method for patients with massive hemorrhage of the upper digestive tract. A few of the patients with plentiful collateral circulation in gastric fundus and pericardia and recurrent upper gastrointestinal bleeding, had no change of FPP or a slightly elevated FPP after PAD and might have had rehemorrhage shortly after PAD operation.

One typical male patient had a massive hemorrhage of upper digestive tract combined with primary peritonitis, jaundice and ascites, and underwent emergency PAD. His hemorrhage ceased, and liver function and general state improved. Four years later, the patient had a massive rehemorrhage of upper digestive tract without jaundice and ascites, and received emergency MCS with a diameter of the anastomotic stoma in 10 mm. From then on, we followed him up continuously and found no reblooding and hepatic encephalopathy. Animal experimental study showed that during cirrhotic portal hypertension, the defensive capacity of mucosa is progressively weakened, resulting in pathologic changes of the gastric mucosa. After disconnection of portazygous junction, desquamation of the epithelial cells of the gastric mucosa, edema and thickening of the submucosal layer, and narrowing of its capillaries occur. The epithelium of the gastric mucosa is obviously ischemic and hypoxic, the defensive capability of the gastric mucosa is further deteriorated, indicating that it is one of the causes of high hemorrhage rate after disconnection. A few patients may have reblooding shortly after PAD.

Another typical case, a female, had recurrent bleeding four times (hematemesis and hemafecia) accompanied with hydrothorax and ascites within 3 mo, underwent emergency PAD, then she could take food as her hydrothorax and ascites gradually receded. Seventeen days after operation, hematemesis occurred, she had a massive rehemorrhage of upper digestive tract the next day, balloon tamponade compression had no effect on hemostasis. Two days later, emergency MCS was performed, 1,000 mL ascites was found during operation, then reblooding ceased. The reblooding of this case was due to the pathologic changes of the gastric mucosa that resulted from PAD.

Based on the above data about PAD, the operation indications for PAD include: massive bleeding of upper digestive tract which cannot be controlled by non-surgical methods; the FPP < 3.92-4.41 kPa (40-45 cm H$_2$O) after splenectomy; esophageal varicos, splenomegaly, anteroposterior diameter of the spleen > 7 cm and apparent hypersplenism; recurrent...
bleeding of the upper digestive tract, debility or poor condition, and poor liver function; rebleeding after DSCS or DSRS, thrombosis of anastomotic stoma of splenic vein; regional portal hypertension.

**PSS**

PAD combined with small stoma PSS is widely used in the therapy of portal hypertension\[^{15,16}\]. The diameter of the anastomosis stoma of PSS mentioned in this paper was from 6 to 8 mm. Small-diameter portacaval shunt for patients is in favor of hepatic reserve\[^{17,18}\]. After PSS, the FPP level was (3.15±0.39) kPa and the incidence rate of rehemorrhage of upper digestive tract reduced by alleviating pathological changes of gastric mucosa and prevented the formation of lateral branch circulation. In order to preserve hepatopetal perfusion to support and improve liver function, the FPP should be maintained at the level no more than (3.92-4.41) kPa. The FPP level was as high as 9.58% (16/167) in patients treated with PSS, which might be associated with improper selection of patients and large anastomotic stoma. In recent years, we have performed some kinds of PSS with small caliber and low blood flow discharge such as inferior meso-caval shunt (IMCS)\[^{19}\], inferior meso-left renal vein shunt\[^{20,21}\] and branch of mesenterico-caval shunt (BMCS), which are technically easy to operate and popularize. Experimental animal study suggested that the portacaval shunt significantly improves the microcirculation of gastric mucosa\[^{22}\] and can promote gastric mucosa to synthesize and secrete glycoprotein and prostaglandins, thus increasing the defensive capability of the gastric mucosa\[^{23,24}\]. It was reported that the levels of plasma renin activity (PRA), angiotensin converting enzyme (ACE), angiotensin II and portal venous pressure (PVP) decrease significantly in cirrhotic patients with portal hypertension after portacaval shunts, which may be the major causes of ascites disappearance in cirrhotic patients after portacaval shunt\[^{25}\]. Surgical PSS might be considered for acute or chronic portal bleeding if medical treatment fails\[^{26}\]. Some kinds of diseases must be operated with PSS, such as extrahepatic portal vein obstruction and portal hypertension resulting from biliary cirrhosis of liver due to bile duct stenosis.

The operation indications for PSS include recurrent multiple bleeding of the upper digestive tract and liver function in Child’s grades A and B status, no ascites, extrahepatic portal vein obstruction, portal hypertension resulting from biliary cirrhosis of liver due to hepatic duct stenosis, rebleeding after PAD, and rebleeding after PAD combined with PSS.

**Selective shunt (SS)**

The theoretical bases for designing selective shunt (SS) are as follows\[^{27-29}\]. PSS (unselective shunts) is effective in hemostasis of the upper digestive tract, but it decreases portal perfusion leading to deterioration of liver function\[^{29,30}\]. PAD aggravates pathologic changes of gastric mucosa and has a high rate of rebleeding. The functional reserve of the liver depends on portal perfusion\[^{27,31}\]. These thoughts have led to the development of selective portasystemic shunts. Warren first reported DSRS in 1967\[^{32}\], and Inokuchi designed and reported coronary vein-caval shunt in 1968\[^{33}\] and 1969\[^{34}\]. Holmin et al.\[^{35}\], operated DSRS in rats in 1977, Bhalerao et al.\[^{36}\], firstly reported DSRS in patients in 1978. Since 1984, Cai et al.\[^{37}\], have begun to operate DSRS in patients in China. Preliminary data indicate that DSRS in a subgroup of patients with good liver function and a correct portalazygous disconnection, more effectively prevents varical rebleeding than endoscopic sclerotherapy\[^{38}\]. It was reported that DSCS selectively improves microcirculation and functions of the gastric mucosa\[^{39}\]. DSCS and PAD are better than MCS and PCS (portacaval shunt) in protecting the hepatic reserve function in rats with cirrhotic portal hypertension\[^{40-44}\]. Experimental study also revealed that the blood viscosity after DSCS is lower than that after PAD\[^{45}\]. DSRS and DSCS have all the advantages of both PAD and PSS, but they are technically difficult. The incidence rates of rebleeding and hepatic encephalopathy in our patients treated with SS were lower compared to the patients treated with other kinds of operation, which might be partly associated with the different conditions of patients. Our results are in accord with other reports\[^{46-49}\].

Gradual development of encephalopathy also exists after selective shunts, and is related with loss of hepatic perfusion of portal blood\[^{50}\]. Based on other reports, portal blood flows to the liver in the early postoperative period in about 88% of patients but in about 42% after 3 years; no patient with a continuing flow of portal blood to the liver suffers from encephalopathy. Final loss of portal blood flow may be due to continuing superior mesenteric venous hypertension causing the development of collateral vessels which convert the selective shunt to an unselective shunt. The selective shunts have not yet been shown to improve long-term survival, which may in any case be limited by progressive liver disease, but their advantages in the shorter term may allow more patients a better survival.

The role of selective shunts in the treatment of gastrointestinal bleeding due to portal hypertension is still controversial. It has already established that it is not suitable to patients with ascites because it may become uncontrollable after the operation and cannot improve portal flow to the liver. It should never be done when there is centrifugal portal blood flow, as in the Budd-Chiari syndrome.

The operation indications for SS include liver function stabilized in Child’s grade A or B, portal blood flow velocity higher than 8-10 cm/s, degree I or II of portal vein displaying during arterial portography\[^{51}\], more than 1.96 kPa (20 cm H₂O) of the difference between splanchic obstructive portal pressure (SOPP) and free portal pressure (FPF), no active hepatitis, esophageal varicosities with history of hemorrhage or severe esophageal varicosity without history of hemorrhage, splenomegaly and anteroposterior diameter of the spleen >7 cm and no apparent hypersplenism, no chronic pancreatitis and splenic phlebitis or periphebitis, no ascites, no retro-peritoneal edema, no Budd-Chiari syndrome.

**Combined PSS+PAD**

Compared to PAD, PSS+PAD had a higher operative mortality, but their postoperative hemorrhage incidence rates had no difference. The number of our cases that underwent
PSS+PAD was too small to induce a definite objective evaluation.

PSS+PAD was performed in the early 1980s. Huang Yaoquan[10] reported the experience of 33 cases operated with PSS+PAD. Then some similar reports showed that this type of operation cannot only decrease free portal pressure to achieve the goal of persistent hemostasis, but also not reduce excessive hepatopetal blood flow[16,32]. After PAD, spontaneous shunt will be gradually emerged. PSS+PAD, ahead of schedule replaces spontaneous shunt, which slowly occurs after PAD with artificial shunt in operation. Combined devascularization and splenorenal shunt (PAD+PSS) significantly decreases portal venous flow and portal pressure, as well as maintaining hepatopetal flow, thus entailing fewer complications compared to either PAD or PSS, some scholars even advocated that PSS+PAD could be a primary selection in the operations for portal hypertension[53,54].

Compared to PSS or PAD, PSS+PAD prolongs operation time, aggravates surgical trauma, and damages liver function, which are the reasons why PSS+PAD cannot be generally performed. Based on the incomplete statistics of 24 famous Chinese hospitals in 1998, only 204 (only accounted for 1.7%) cases received PSS+PAD in more than 12 000 cases of operations for portal hypertension[60].

Prognosis of the patients is mainly dependent on the condition of the whole body and hepatic function. We should select the operations which have minimal adverse effect on the whole condition and liver function in the patients. PSS has few advantages because of a negative effect on hepatic blood perfusion in contrast to PAD. In China, Yang Zhen and Qiu Fazu[6,50] reported that patients that underwent standard PAD have a postoperative rebleeding incidence rate lower than 10%. Thus, it should be emphasized that surgeons should be careful when choosing PSS+PAD as a treating method for the patients with portal hypertension.

The operation indications for PAD combined with small stoma PSS (usually mesocaval shunt or portacaval shunt) include recurrent or massive bleeding of varices of esophagus and gastric fundus and stable liver function in Child’s grades A and B, overt varices of esophagus and gastric fundus and Child’s grade A status of hepatic function with FPPs more than 3.92-4.41 kPa (40-45 cm H2O), ascites, and a relatively younger age (generally less than 60 years).

**Surgical treatment of primary hepatic carcinoma concurrent with portal hypertension**

Surgical treatment of primary hepatic carcinoma complicated by portal hypertension is based on appraisal of hepatosis and prediction of life expectancy of the patients with portal hypertension[57,58]. The 5-year survival rate of the patients with liver cirrhosis and hemorrhage of upper digestive tract is 25-35%. Pinto et al[60], reported that 287 patients with hemorrhage of the upper digestive tract have a total 5-year survival rate of 26.2%, and that hepatic function condition of the patients exerts great effects upon their survival. Yang et al[60], reported that poor liver function increases postoperative rebleeding and mortality. Zhang et al[31], showed that onestage hepatocellular carcinoma excision and splenectomy and portal azygous disconnection can be simultaneously performed for patients with good hepatic function. Our data showed that hepatectomy and portacaval shunt greatly exacerbate the hepatic function, if these two operations are performed simultaneously.

During the treatment of patients with hepatocellular carcinoma and portal hypertension, the following must be considered. Hepatic function of the patients is a fundamental factor in determining the prognosis and long-term survival. In recent years, many domestic hospitals have performed whole liver transplantation in order to treat the liver-function decompensation (Child’s grade C or more serious) patients with hepatocellular carcinoma (mainly small HCC) and upper gastrointestinal hemorrhage due to portal hypertension, and have achieved good therapeutic effects. Prophylactic PAD and PSS should not be done for the patients with varices of esophagus and gastric fundus but without upper gastrointestinal hemorrhage. One-stage hepatectomy and PAD (splenectomy and pericardia disconnection) should be a better choice for patients with HCC and portal hypertension[62]. Interventionsal therapy (hepatic artery embolism) plus PAD and hepatectomy plus either sclerotherapy or loop ligature can reduce operational risk[63,64].

**Liver transplantation**

Liver transplantation can treat portal hypertension, and rehemorrhage, and encephalopathy do not occur in treated patients. Liver transplantation was carried out abroad much earlier. The domestic practice of liver transplantation in recent years indicates that liver transplantation is feasible not only in patients with chronic progressive hepatic failure, refractory ascites and jaundice, but also in patients with recurrent hemorrhage, especially with poor hepatic function, if they are not old and their other vital organs function well. For example, one patient with multiple upper gastrointestinal bleeding received repeated sclerotherapy and TIPS, but no effective results were achieved. He then underwent a whole liver transplantation because of carcinomatous changes in his liver, and his free portal pressure decreased to normal level and conditions were very satisfactory.

In China, most patients who underwent liver transplantation were those with advanced-stage hepatocellular carcinoma and malignant diseases of biliary tract, the few were those with benign irreversible liver diseases including liver failure and recurrent upper gastrointestinal hemorrhage.

The indication for liver transplantation is end-stage liver disease. Not all patients with variceal bleeding have end-stage liver disease, and not every patient with variceal bleeding needs a new liver. Although the availability and increasingly successful outcome of liver transplantation have significantly altered the management of patients with cirrhosis, the question “does this patient really need a transplant now, or is the patient likely to need a transplant in the future?” should always be asked.

We believe that the therapy of hepatic cirrhosis and portal hypertension complicated by upper digestive
hemorrhage will change greatly.

**Portacaval shunt for patients with portal hypertension and ascites**

Many researches have confirmed that blood renin activity of the patients with liver cirrhosis and portal hypertension, especially those with ascites, increases obviously. Vice versa, increased renin activity can raise portal vein pressure (PVP) via initiating renin–angiotensin–aldosterone system and plays an important role in ascites due to cirrhosis.

The reasons why their ascites disappear after portacaval shunt are as follows. Portal vein pressure (PVP) decreases significantly. After portacaval shunt, returned blood volume and effective blood volume increase, and then renal blood flow relatively raises, making the juxtaglomerular cells secrete less renin. The blood level of glucagons reduced by flow relatively raises, making the juxtaglomerular cells secrete significantly. After portacaval shunt, returned blood volume shunt are as follows. Portal vein pressure (PVP) decreases and plays an important role in ascites due to cirrhosis.

(PVP) via initiating renin–angiotensin–aldosterone system versa, increased renin activity can raise portal vein pressure of the patients with liver cirrhosis and portal hypertension, many researches have confirmed that blood renin activity of patients after portacaval shunt operation. We should use a small diameter (6-8 mm) of anastomosis stoma of portacaval shunt as best as we can.

**Emergency operation for upper gastrointestinal massive hemorrhage due to portal hypertension**

The results in our study demonstrate that emergency operation rank non-negligible position in the treatment of portal hypertension.

Once the varices rupture, the chance of rehemorrhage is very high shortly after the first hemorrhage, and the mortality rate due to rehemorrhage is nearly twice that of the first hemorrhage. Thus, the indications of emergency surgery include massive hemorrhage which cannot be controlled within 12 h, recurrent massive upper gastrointestinal hemorrhage, and no obvious surgical contraindications.

Which surgical procedure should be adopted depends upon the condition of patients, liver function and findings in surgery. Generally, shunt operation can be performed in patients with relatively better condition and liver function, a great quantity of collateral vessels surrounding the spleen and higher portal pressure (>3.43 kPa or 35 cm H₂O). On the contrary, patients with poor body condition and liver function, a few collateral vessels, obvious atrophy of liver volume and portal vein pressure less than 3.43 kPa (35 cm H₂O), are fit for splenectomy and disconnection. Our data showed that only a slight difference in operative mortality between the two groups of patients was found, and that no operative mortality and encephalopathy occurred in the PAD group, suggesting that PAD can be performed when possible.

With regard to emergency operation, we should decide whether the spleen is resected according to the condition of patients. It was reported that splenic artery ligation in these patients achieves the same therapeutic effects as splenectomy. Therefore, when the patients undergo disconnecting combined with shunting (except for splenorenal shunt), their spleen may not be excised, and splenic artery may be ligated.

It was considered previously that the patients with poor liver function should not be operated because of high operative mortality. In the shunting group in this article, three of seven patients with Child’s grade C died of surgical treatment. In the disconnecting group in this article, none of the three patients with Child’s grade C died of PAD operation, suggesting that surgical therapy should be taken and PAD is the proper selection for patients with poor liver function.

In regard to the surgical therapy of patients with portal hypertension, a suitable surgical procedure can achieve satisfactory therapeutic results. Different patients at different stages in their disease may require different therapies. An emphasis of this management is the full evaluation of the underlying liver disease. Our data showed that PAD as a major operation accounted for 50.39% of all the operations in this article. If the diameters of anastomotic stoma of PSS are restricted, favorable therapeutic effects can be achieved. When PSS needs to be conducted, the diameter of the anastomotic stoma should be 6-8 mm and the most usual operative approach is side-to-side meso-caval shunt. Selective shunt is a relatively ideal surgical procedure, but technically it is difficult. Although disconnection plus shunt seems to be a better procedure of choice because it can lower the portal pressure and maintain the portal flow, it will give the patient a big strike and should be carefully selected according to the liver function of patients. Liver transplantation can treat portal hypertension and achieve better long-term results, but it should not be the first choice in treating portal hypertension in China. Doctors should evaluate liver function comprehensively of patients with hepatocellular carcinoma and portal hypertension and carefully select combined operation in order to prolong their survival time. The cirrhotic patients with ascites can be treated with PSS with a small diameter (6-8 mm) of the stoma anastomosis. If acute continuous gastrointestinal varical bleeding in cirrhotic patients cannot be controlled by medical treatment, and if no operational contraindication exists, emergency surgical treatment should be given immediately.

**REFERENCES**

1. Isaksson B, Hultberg B, Hansson L, Bengtsson F, Jeppsson B. Effect of mesocaval interposition shunting and repeated sclerotherapy on blood levels of gastrointestinal regulatory peptides, amino acids, and lysosomal enzymes-a prospective randomised trial. *Liver* 1999; 19: 3-11.

2. Malesci A, Tacconi M, Valentini A, Basilico M, Lorenzano E, Salerno F. Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function. *J Hepatol* 1997; 26: 816-825.

3. Gulberg V, Haag K, Rossle M, Gerbs AL. Hepatic arterial buffer response in patients with advanced cirrhosis. *Hepatology* 2002; 35: 630-634.

4. Miyamoto Y, Oho K, Kumamoto M, Toyonaga A, Sata M. Balloon-occluded retrograde transvenous obliteration improves liver function in patients with cirrhosis and portal hypertension. *J Gastroenterol Hepatol* 2003; 18: 934-942.

5. Asakura T, Ohkohchi N, Orii T, Koyama M, Tsukamoto S, Sato M, Enomoto Y, Usuda M, Satomi S. Portal vein pressure is the key for successful liver transplantation of an extremely small graft in the pig model. *Transplant Int* 2003; 16: 376-382.

6. Qiu FZ, Evaluation of the pericardial devascularization in portal hypertension. *Zhonghua Waike Za Zhi* 1983; 21: 275-277.

7. Huang YT, Wang WM, Wang JQ, Bai CN. Surgical treatment
of portal hypertension: 45 year experience. Zhonghua Waike Zazhi 2000; 38: 85-88

8 Chen FM, Wang JY, Huang TJ, Hsieh JS. The effect of portal hypertension on the glycoprotein biosynthesis of rat gastric mucosa. J Invest Surg 2002; 15: 311-317

9 Thuluvath PJ, Yoo HY. Portal hypertensive gastropathy. Am J Gastroenterol 2002; 97: 2973-2978

10 Ohta M, Yamaguchi S, Gotoh N, Tomikawa M. Pathogenesis of portal hypertensive gastropathy: a clinical and experimental review. Surgery 2002; 131(Suppl): S165-S170

11 Liu JK, Cai JX, Wang AC, Yang HW. Studies of functional and morphological changes of gastric mucosa after portoazygous disconnection in cirrhotic portal hypertension in rats. Disan Junji Daxue Xuebao 1994; 16: 252-255

12 Chen L, Yang L, Yang Z, Dae Z. Magnetic resonance angiography in assessing changes of pre-and post-disconnective portal system in patients with portal hypertension. Zhonghua Waike Zazhi 2000; 38: 92-94

13 Guan H, Chen Y, Qian H. Expression of endothelin-1 and nitric oxide synthase mRNA in gastric mucosa of rats with cirrhosis and portal hypertensive gastropathy after disconnective operations. Zhonghua Yixue Zazhi 1998; 78: 702-703

14 Kojima K. Experimental and clinical studies on esophageal hemodynamics in the Sugiura procedure. Nippon Geka Gakkai Zasshi 1986; 87: 488-498

15 Xue H, Zhang H, Zhang Y, Jiang Q. Portal anticoagulation in preventing thrombosis after portaozygous devascularization for portal hypertension. Zhonghua Waike Zazhi 2000; 38: 855-857

16 Gao D, He Z, Wu J, Ma Q, Song H, Mei L, Wu Y. Long-term results of combined splenorenal shunt and portaozygous devascularization in patients with portal hypertension. Zhonghua Waike Zazhi 1998; 36: 327-329

17 Rosemurgy AS, Zervos EE, Bloomston M, Durkin AJ, Clark WC, Goff S. Post-shunt resource consumption favors small-diameter prosthetic H-graft portacaval shunt over TIPS for patients with poor hepatic reserve. Ann Surg 2003; 237: 820-827

18 Leng X, Zhu J, Du R. Portacaval shunt with H-grafts of small diameter in treating cirrhotic patients with portal hypertension. Zhonghua Waike Zazhi 1998; 36: 330-332

19 Cai J, Dong J, Gu H. Inferior mesocaval shunt. Zhonghua Waike Zazhi 1996; 34: 151-153

20 D’Cruz K, Natarajan A. Emergency inferior mesenteric vein to left renal vein shunt in varical bleeding: an alternative technique. Trop Gastroenterol 2001; 22: 230-231

21 Rahmani O, Wolpert LM, Dreznier AD. Distal inferior mesenteric veins to renal vein shunt for treatment of bleeding anorectal varices: case report and review of literature. J Vasc Surg 2002; 36: 1264-1266

22 Trigger DR. Portal hypertensive gastropathy. Baillieres Clin Gastroenterol 1992; 6: 481-495

23 Ekelund M, Hakansson R, Holmin T, Oscarson J, Rehfeld JF, Sundler F, Westrin P. Effects of portacaval shunt on the rat stomach. Acta Physiol Scand 1985; 124: 437-447

24 Liu Jikui, Cai JX, Duan HC, Yang HW. Effects of portacaval shunt on gastric mucosa in cirrhotic rats with portal hypertension. Zhonghua Shiyan Waike Zazhi 1997; 14: 18-20

25 Zhang Z, Feng H, Leng X, Ma F, Wang B, Du R. The levels of ninin in plasma, angiotensin converting enzyme and angiotensin II in cirrhotic patients with ascites undergoing portacaval shunt. Zhonghua Waike Zazhi 1999; 37: 366-368

26 Primignani M, Dell’Era A, Fazzini L, Lotelli S, de Franchis R. Portal hypertensive gastropathy in patients with cirrhosis of the liver. Recent Prog Med 2001; 92: 735-740

27 Gusberg RJ. Distal splenorenal shunt-perspective, practical, perspective, practice. Dig Dis 1992; 10(Suppl): 84-93

28 Mercado MA, Orozco H, Ramirez-Cisneros FJ, Hinojosa CA, Plata JF, Altomare J. Diminished morbidity and mortality in portal hypertension surgery: relocation in the therapeutic armamentarium. J Gastrointest Surg 2001; 5: 499-502

29 Zhu J, Liu F, Leng X. Perioperative plasma amino acid spectrum analysis in portal hypertensive cirrhotic patients undergoing portacaval H-graft shunt. Zhonghua Waike Zazhi 1997; 35: 299-301

30 Feng H, Zhang Z, Leng X, Li S, Zhu J, Du R. Plasma level of glucagon in cirrhotic patients with portal hypertension during operation of portacaval shunts. Zhonghua Waike Zazhi 1999; 37: 222-224

31 Weng Y, Wang Y, Xue J, Zhang Z, Zhou Y, Chen D, Li C. The influence of side-to-side portacaval shunt plus enhancement of perfusion of hepatic artery on cirrhotic liver, an experimental study. Zhonghua Waike Zazhi 1998; 36: 487-490

32 Warren WD, Zeppe R, Fomon JJ. Selective trans-splenic decompression of gastroesophageal varices by distal splenorenal shunt. Ann Surg 1967; 166: 437-455

33 Inokuchi K. A selective portacaval shunt. Lancet 1968; 2: 51-52

34 Inokuchi K, Kobayashi Y. Selective shunt method for portal hypertension—our method of the left gastric venous-caval shunt. Shujitsu 1969; 23: 138-150

35 Holmin T, Schroder R, Berchtold R. A technique for distal splenocaval shunt in the rat. World J Surg 1977; 1: 661-665

36 Bhalaria RA, Pinto AC, Bapat RD, Shetty SV, Bhide PD, Wainganankar VS, Kirtane JM, Mehendale VG, Shetty SD. Selective transsplenic decompression of oesophageal varices by distal splenorenal and splenocaval shunt. Gut 1978; 19: 851-857

37 Cai J, Dong J, Gu H, Bie G, Wang S, Sun W, Liu J, Zhou Y, Peng Z, Wang A. Distal splenocaval shunt in 66 patients with portal hypertension. Zhonghua Waike Zazhi 1998; 36: 336-338

38 Spina GP, Santambrogio R, Opoche R, Cosentino F, Zambelli A, Passoni GR, Cucchiaro G, Macri M, Morandi E, Bruno S. Distal splenocaval shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Ann Surg 1990; 211: 178-186

39 Liu JX, Cai JX, Duan HC, Yang HW. Effects of distal splenocaval shunt on gastric mucosa in cirrhotic portal hypertension in rats. Zhonghua Shiyan Waike Zazhi 1997; 14: 104-105

40 Xu XB, Cai JX, Dong JH, Han BL. Effects of different operations on mitochondrial respiratory function of cirrhotic liver in rats. Disan Junji Daxue Xuebao 1996; 18: 48-51

41 Wu G, Cai JX, Dong JH, Duan HC. Effects of different types of operation on hepatic reserve function in rats with cirrhotic portal hypertension. Disan Junji Daxue Xuebao 1998; 20: 37-39

42 Xue XB, Cai JX, Dong JH, Han BL, Lin K, Leng XS. Effects of the different procedures on the Portasystemic shunting and the hepatic function in the rats. J Dig Surg 2004; 3: 46-49

43 Xu XB, Cai JX, Dong JH, He ZP, Han BL, Leng XS. Effects of different operations on cirrhotic portal hypertensive liver in rats. Shijie Huaren Xiaohua Zazhi 2004; 12: 689-693

44 Xu XB, Cai JX, Dong JH, He ZP, Han BL, Leng XS. Effects of portaozygous disconnection, portacaval shunt and selective shunts on experimental rat liver cirrhosis. Zhonghua Ganzang Bing Zazhi 2005; 13: 113-116

45 Li MX, Wang AC, Cai JX. Effects of distal splenocaval shunt on hemodynamics. Disan Junji Daxue Xuebao 1993; 15: 532-535

46 Millikan WJ Jr, Warren WD, Henderson JM, Smith RB 3rd, Salam AA, Galambos JT, Kuttner MH, Keen JH. The Emory prospective randomized trial: selective versus nonsselective shunt to control variceal bleeding. Ten year follow-up. Ann Surg 1985; 201: 712-722

47 Henderson JM, Kuttner MH, Millikan WJ Jr, Galambos JT, Riepe SP, Brooks WS, Bryan FC, Warren WD. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis. A prospective, randomized trial. Ann Intern Med 1990; 112: 262-269

48 Raia S, da Silva LC, Gayotto LC, Forster SC, Fukushima J, Strauss E. Portal hypertensive cholestasis in schistosomiasis: a long-term follow-up of a randomized trial comparing three types of surgery. Hepatology 1994; 20: 398-403

49 Rikkers LF, Rudman D, Galambos JT, Fulenwider JT, Millikan...
WJ, Kutner M, Smith RB 3rd, Salam AA, Sones PJ Jr, Warren WD. A randomized, controlled trial of the distal splenorenal shunt. Ann Surg 1978; 188: 271-282

50 Nordlinger BM, Nordlinger DF, Fulenwider JT, Millikan WJ, Sones PJ, Kutner M, Steele R, Bain R, Warren WD. Angiography in portal hypertension: clinical significance in surgery. Am J Surg 1980; 139: 132-141

51 Huang YQ, Zhong YF. Evaluation of the remote results of various procedures in the treatment of portal hypertension. Zhonghua Waike Zazhi 1986; 24: 722-724

52 Cao Y, Cui L, Meng F, Wang M, Wang R, Han W. Treatment of portal hypertension by using pericardial vascular disconnection and mesocaval side-to-side shunting. Zhonghua Waike Zazhi 1998; 36: 339-341

53 Xu CE, Zhang SG, Yu ZH, Li GX, Cao LL, Ruan CL, Li ZT. Combined devascularization and proximal splenorenal shunt: is this a better option than either procedure alone? Hepatobiliary Pancreat Surg 2004; 11: 129-134

54 Li Z, Zhao L, Yu Z, Zhong Z. Effect of combined operation including splenorenal shunt as the main technique for portal hypertension in children. Zhonghua Waike Zazhi 2000; 38: 601-603

55 Huang CT, Wang WM, Dai ZB. Survey of surgical treatment to portal hypertension in China. Zhonghua Waike Zazhi 1998; 36: 324-326

56 Yang Z, Qiu F. Pericardial devascularization with splenectomy for the treatment of portal hypertension. Zhonghua Waike Zazhi 2000; 38: 645-648

57 Úeo W, Sung JY, Chung SCS. A prospective study of upper gastrointestinal hemorrhage in patients with hepatocellular carcinoma. Dig Dis Sci 1995; 40: 2516-2521

58 Minagawa N. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 2001; 233: 379-384

59 Pinto HC, Abrantes A, Esteves AV. Long term prognosis of patients with cirrhosis of the liver and upper gastrointestinal bleeding. Am J Gastroenterol 1989; 84: 1239-1243

60 Yang W, Wang GJ, Ding SQ, Liu QG, Pan CE. Surgical management of liver carcinoma accompanied by portal hypertension. Zhonghua Pu tong Waike Zazhi 2002; 17: 200-201

61 Zhang ZL, Hu JK, Jin ZT. Surgical treatment for hepatocellular carcinoma and concomitant portal hypertension. Zhongguo Shiyong Waike Zazhi 2002; 22: 85-87

62 Li H, Hu YL, Wang Y, Zhang DS, Jiang FX. Simultaneous operative treatment of patients with primary liver cancer associated with portal hypertension. Hepatobiliary Pancreat Dis Int 2002; 1: 92-93

63 Chen WC, Hou MC, Lin HC. Feasibility and potential benefit of maintenance endoscopic variceal ligation patients with unresectable hepatocellular carcinoma and acute esophageal variceal hemorrhage: a controlled trial. Gastrointest Endosc 2001; 54: 18-23

64 Letier MH, Krige JE, Lemmer ER, Terblanche J. Injection sclerotherapy for variceal bleeding in patients with irresectable hepatocellular carcinoma. Hepatogastroenterology 2000; 47: 1680-1684

65 Zhang ZM, Leng XS, Feng HQ, Zhang WF, Pan T, Du RY. The changes of plasma renin activity in cirrhotic patients with ascites undergoing portacaval shunt. Zhonghua Pu tong Waike Zazhi 2001; 16: 395-396

66 Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, Torras X, Rodriguez J, Such J, Pascual S, Soriano G, Perez-Mateo M, Guarnier C. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003; 37: 1147-1153

67 Jalan R, Hayes PC. Sodium handling in patients with well compensated cirrhosis is dependent on the severity of liver disease and portal pressure. Gut 2000; 46: 527-533

68 Orozco H, Mercado MA, Martinez R, Tiavel M, Chan C, Vazquez M, Zenteno-Guichard G, Pantoya JP. Is splenectomy necessary in devascularization procedures for treatment of bleeding portal hypertension? Arch Surg 1998; 133: 36-38

69 Xu R, Ling Y, Qiu W. The different influences of splenectomy plus ligation of pericardial vein and shunt on portal hypertensive gastropathy. Zhonghua Waike Zazhi 1997; 35: 515-517

Science Editor Wang XL  Language Editor Elsevier HK